MARKHAM, ON--(Marketwire - August 09, 2010) - Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce Health Canada approved 11 of their prescription and non-prescription drugs. All of these drugs are now being sold in Canada and have been submitted to Latin America for approval and distribution throughout their continent. Management anticipates annual sales from their recently approved drugs to exceed $6 million.
The current list of drugs which have been approved by Health Canada include:
- Triferrex 150 which is a non-constipating iron supplement for men and women
- Triferrex Pre-Natal (PN) which is a non-constipating multi-vitamin to be used prior to, during and after pregnancy (post partum)
- Gravagol, used for the treatment of migraine headaches
- Monurol, used as a onetime treatment for urinary tract infections in women
- Urasol, a non-antibiotic for long-term treatment of urinary tract infections
- Somonol, used as a hypnotic
- Soropon, used exclusively in the treatment of cradle cap in infants
- Vivol, used as tranquilizer to relieve stress and tension
- Kemsol, used to help treat scleroderma which is a skin disease
- Hydraxx 1 percent (fragrance), used by dermatologists for very dry skin
- Hydraxx 2 percent (non-fragrance), used by dermatologists for very dry skin
"This is an exciting time for our company. We continue to introduce effective, new, high demand prescription and non-prescription drugs into the market. Our 11 Health Canada approved drugs are anticipated to generate over $6 million in annual sales. All of these products are sold under the Axxess Pharma brand name," stated Gerald Sequeira, President/CEO. "We look forward to receiving approval on 11 additional drugs within the next 3 months."
For more information, please contact Investor Relations at (973) 351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology,Neurology and Urology.
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.